GLP1R and type 2 diabetes mellitus: These physiological findings have led to clinical trials and the subsequent approval of GLP‐1 receptor (GLP‐1R) agonists, such as exendin‐4 (Ex4), liraglutide and dulaglutide, for treatment of diabetes type II.3, 4, 5, 6, 7, 8, 9